Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Carolyn J. Quinn"'
Autor:
Jedd D. Wolchok, Jennifer H. Menell, Susan E. Krown, Lynne A. Lamb, Carolyn J. Quinn, Theresa Foster, Philip O. Livingston, Wen Jen Hwu, Janene Merrell, Linda Williams, Katherine S. Panageas, Paul B. Chapman, Alan N. Houghton
Publikováno v:
Journal of Clinical Oncology. 21:3351-3356
Purpose: To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases. Patients and Methods: Patients with histologically confirmed advanced-stage metastatic melanoma we
Autor:
Katherine S. Panageas, W. Hwu, Carolyn J. Quinn, P. O. Livingston, Paul B. Chapman, Jedd D. Wolchok, Lawrence J. Williams
Publikováno v:
Melanoma Research. 12:381-387
Phase II studies of biochemotherapy in metastatic melanoma patients have reported response rates of 47-63%. Even though these were highly selected patients, we were intrigued by these promising response rates and began using this regimen as standard
Autor:
Carolyn J. Quinn, Philip O. Livingston, Paul B. Chapman, Y. B. Su, Linda Williams, Sejean Sohn, Kent A. Sepkowitz, Jedd D. Wolchok, Susan E. Krown, Theresa Foster
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 22(4)
Purpose Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine. Extended TMZ dosing regimens may be superior by deliverin
Autor:
Linda Williams, Carolyn J. Quinn, Wen-Jen Hwu, Paul B. Chapman, Alan N. Houghton, Katherine S. Panageas, Susan E. Krown, Philip O. Livingston, Jennifer H. Menell
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(11)
PURPOSE: To establish a safe and tolerated regimen of an oral cytotoxic agent, temozolomide, and a cytostatic agent, thalidomide, in patients with unresectable stage III or IV malignant melanoma. PATIENTS AND METHODS: Patients with unresectable stage